

Media Central Corporation

08:00 23 Apr 2020

Media Central says online cannabis lifestyle magazine Canncentral.com will cover psychedelics market

Media Central Corporation Inc (CSE:FLYY) said Thursday that its wholly-owned online cannabis lifestyle publication Canncentral.com will provide strong coverage of the burgeoning psychedelics sector.

The Toronto-based media group said that Canncentral's psychedelics reporting will focus on the "wide range of therapeutic and medical applications" as well as "business news, trends and legislative changes" in the rapidly emerging area.

"The world of psychedelics is a natural extension of the content we produce at Canncentral," MediaCentral CEO Brian Kalish said in a statement.

Launched in fall 2019, Canncentral.com is benefitting from referral traffic from its sister publication, NOW Magazine, a weekly newspaper with a strong print and digital presence.

Media Central said leveraging the millions of readers already engaging with its urban publications is expected to yield "tremendous results."

"Our 6.5 million audience of engaged influential readers have their fingers on the pulse of emerging trends and are eager to consume up-to-date information from our award-winning editorial teams," Kalish noted.

"Early signs point to the huge impact that psychedelics will have on society from a cultural, medical and business perspective. This focus on psychedelics is a natural progression of our ongoing strategy to leverage our considerable audience and capitalize on the latest in material trends as we move to further monetize our titles," he added.

For most, psychedelic drugs conjure up images of the 1960's, hippies tripping out on LSD or magic mushrooms. However, Media Central noted that early studies are finding that psilocybin — the active agent in magic mushrooms — could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).

In late 2018, the US Food and Drug Administration (FDA) provided "breakthrough therapy" status to a psilocybin treatment for clinical depression, pushing the industry into the spotlight.

The media group pointed out that in the last 24 months "several US cities have decriminalized psychedelics" for medicinal purposes and pharma giants like Johnson & Johnson, AstraZeneca, Merck & Co., and Pfizer have launched clinical trials to research how psychedelics like LSD, MDMA and ketamine can target a range of medical ailments from cancer to PTSD, to depression to opioid addiction. Similarly, Johns Hopkins University recently launched a research center for psychedelic studies, noted the company, called the Center for Psychedelic and Consciousness Research.

Price: 0.005

Market Cap: \$1.69 m

1 Year Share Price Graph



Share Information

Code: FLYY

Listing: CSE

52 week High Low
0.13 0.005

Sector: Media

Website: www.mediacentralcorp.com

Company Synopsis:

MediaCentral (CSE: FLYY, FSE: 3AT) is consolidating the over 100 million coveted and premium readers of the 100 Alternative Weekly newspapers across North America. Creating the most significant untapped audience of influencers in North America.

action@proactiveinvestors.com

Moreover, Data Bridge Market Research says the psychedelics market is experiencing a compound annual growth rate of nearly 16%. This is driven in part by the expected impact from chemicals such as LSD and Ketamine in the antidepressant drug market, which is tipped to exceed \$15.98 billion by 2023. As a result, many analysts have forecast the potential of the psychedelics market to "outpace cannabis as an investment class," Media Central added.

The Toronto media giant said Canncentral will provide regular coverage on psychedelics and will distribute stories to its growing audience through its own platform, and Media Central's NOW Magazine in Toronto and Georgia Straight in Vancouver.

"Content around psychedelics will be integrated across the company's full spectrum of three digital platforms, two print publications, three newsletters and nine social media channels," it said.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Media Central Corporation named herein, including the promotion by the Company of Media Central Corporation in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).